Linus Health vs Neurotrack (2026)
The most AI native product in the category against the most deployable, and they barely overlap. Linus Health derives signal from behaviour, the drawing process and speech acoustics, and uses it to predict amyloid status, earning A grades on AI centrality, model transparency, evidence, and governance, the fullest technical record of the four. Neurotrack keeps the AI light on purpose and competes on reach: cloud based on any device with no hardware, integrating with all major EHRs in weeks, sized for the Medicare Annual Wellness Visit, with the broadest distribution and the only published SOC 2 of the four. The honest asymmetry is that these solve different problems, one predicts pathology for the treatment era, the other screens a population inside existing workflows. If your failure mode is identifying who carries amyloid pathology, start with Linus, and confirm which claims are cleared versus research. If your failure mode is getting a validated screen in front of an entire panel without friction, start with Neurotrack, understanding it is registered rather than cleared.
- Genuinely AI native: the DCTclock analyses the drawing process, stylus dynamics and speech acoustics with no paper equivalent, graded A on AI centrality where Neurotrack's standardised digital delivery grades C, and A on model transparency for peer reviewed method disclosure where Neurotrack grades B.
- Biomarker prediction is the capability: DCTclock correlated with amyloid PET in cognitively normal people and the DCR predicting PET status in the 930 participant Bio-Hermes-001 study, graded A on clinical evidence where Neurotrack grades B, addressing treatment eligibility rather than screening alone.
- The best governance posture in this sweep: the team names the cultural and educational bias failure mode directly and publishes the uncomfortable findings, including a South Asian cohort, graded A where Neurotrack designs for inclusivity but publishes no subgroup data at B.
- Population scale deployment with no hardware friction: cloud based, runs on any device, no specialised hardware or training, graded A on deployment where Linus requires an iPad with Apple Pencil and grades B.
- The broadest distribution and interoperability in the category: integrates with all major EHRs deploying in weeks, feeding Annual Wellness Visit and RADV workflows, graded A on interoperability where Linus offers integration without naming EHRs and grades B.
- The only published security attestation of the four: SOC 2 and HIPAA stated directly on the product, graded B where Linus has none located, with named health system customers across primary care, virtual, and home settings.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Linus Health and Neurotrack are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Linus Health | Neurotrack |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | 2019 | 2012 |
| Headquarters | Boston, Massachusetts, United States | Redwood City, California, United States |
| Website | linushealth.com | neurotrack.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Linus Health its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Neurotrack, Linus Health grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Neurotrack its top capability grade on EHR and Interoperability Depth, Deployment Model and Data Residency and Setting and Specialty Coverage. Set against Linus Health, Neurotrack grades higher on EHR and Interoperability Depth and Deployment Model and Data Residency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Linus Health or Neurotrack?
On the axes where the AI Health Index separates them, Linus Health grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure, and Neurotrack grades higher on EHR and Interoperability Depth and Deployment Model and Data Residency. Linus Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Linus Health and Neurotrack differ most?
The widest separation the AI Health Index records between Linus Health and Neurotrack is on AI Centrality, where Linus Health grades A and Neurotrack grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Linus Health and Neurotrack grade the same?
The AI Health Index grades Linus Health and Neurotrack the same on several axes, including Autonomy and Oversight Model, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Linus Health and Neurotrack not disclosed?
At the last review, at least one of Linus Health and Neurotrack published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These are the opposite ends of the category on AI and on deployment. Linus is the model driven product, graded A on AI centrality, model transparency, evidence, and governance, its signal derived from behaviour rather than digitised scoring.
Neurotrack is the distribution product, graded A on deployment, interoperability, and setting coverage, its moat the workflow fit and health system reach rather than the algorithm; notably its own earlier eye tracking work, which involved genuine digital phenotyping, was removed from the clinician suite, which is why it grades C on AI centrality today.
Two cautions cut in opposite directions: Linus is cleared for cognitive assessment while its commercial claim is amyloid prediction, much of it in conference abstracts, and it publishes no security attestation; Neurotrack is FDA registered rather than cleared and its evidence base partly predates its current product. Neither publishes pricing.